This downregulation correlates with key clinicopathologic markers, including estrogen receptor (ER), progesterone receptor (PR), and HER2 status [46], suggesting that PIEZO2 expression is closely aligned with tumor hormonal signaling profiles. The gene discussed is PIEZO2; the disease is neoplasm.